Life Sciences Deals: Recap of 2025 and Look Ahead to 2026
In 2025, we had the opportunity to collaborate with our clients on a variety of significant financing, licensing, and M&A deals. These transactions spanned various sectors, including biopharmaceuticals, drug discovery, and enterprise healthcare, showcasing a wide array of deal sizes, structures, and complexities.
Looking forward to 2026, we are keeping a close eye on several key themes that are shaping the landscape of dealmaking:
One prevalent trend is precision-led, asset-centric M&A activities aimed at replenishing pipelines and counteracting the loss of exclusivity. Dealmaking is expected to emphasize cutting-edge science and assets in late-stage or nearing launch in the fields of oncology, immunology, cardiometabolic, and CNS. Buyers will prioritize assets with strong safety profiles, clear paths to pivotal data, and robust launch strategies. The demand for innovative and distinct products will remain high as patent expirations and asset scarcity continue to pose challenges. Consequently, major pharmaceutical companies are likely to engage in targeted acquisitions to address gaps in their portfolios.
The utilization of alternative deal structures and private capital is also anticipated to expand to mitigate risks. Strategies such as royalty agreements, earn-outs, options, minority stakes, and staged structures will be utilized to manage technical, regulatory, and reimbursement uncertainties. Private equity and structured financing tools are becoming increasingly mainstream, facilitating the transition from late-stage development to commercialization. Due to ongoing fluctuations in valuations, milestone-driven earn-outs and licensing arrangements will aid in advancing transactions while upholding governance and ensuring returns.
Moreover, cross-border licensing and co-development collaborations, primarily from China to the West, are becoming more customary. Western pharmaceutical companies are forging partnerships with Chinese counterparts through well-structured licensing agreements, regional rights allocations, and enhanced data/IP oversight to mitigate security and supply-chain risks. China’s burgeoning biotech sector is generating novel assets and actively licensing them on a large scale, supported by regulators’ acceptance of multi-regional clinical trial data. As we move into 2026, we can expect to witness a surge in cross-border collaborations, with co-development initiatives and regional commercialization models accelerating global market penetration.
In addition, the integration of AI in due diligence processes and post-close value creation activities is increasingly becoming indispensable. AI technologies are streamlining diligence timelines by enhancing assessments of technical and regulatory achievements, safety profiles, value projections, and integration strategies, resulting in faster and more informed decision-making processes. In the upcoming year, investments are expected to shift towards embedding AI across various areas such as R&D, manufacturing, and commercial integration. Successful teams will leverage analytics from pre-deal evaluations to post-deal integration to synergize capital allocation with clinical data, thereby enhancing value realization.
Furthermore, factors such as policy changes, pricing considerations, and geopolitical dynamics are reshaping deal modeling and valuation strategies. Proposals resembling Most Favored Nation (MFN) pricing, tariffs, FDA reorganizations, and alterations in EU policies are prompting deal teams to consider a broader range of pricing, approval, and supply-chain scenarios in their analyses. Potential MFN-driven alterations may affect the actualization of prices in the U.S. and impact product launch sequences, with heightened vigilance around Medicaid involvement and spillover effects in the upcoming year. Enhanced scrutiny on cross-border activities, particularly concerning China-based licensing and Active Pharmaceutical Ingredient (API) sourcing, is heightening the focus on IP protection, operational footprint, and tariff vulnerabilities.
We are proud to showcase select transformative transactions facilitated for our life sciences clients in 2025, and we eagerly anticipate supporting their strategic moves in 2026.